Advantages of NGS for MRD testing

Products are for professional/laboratory use only Explore Recent Scientific Contributions Using Invivoscribe’s Products Key opinion leaders across the world have recently published papers that discuss the advantages of using highly sensitive next-generation sequencing (NGS) for Minimal Residual Disease (MRD) testing.

Invivoscribe’s EHA Symposiums Now Available on Demand

Products are for professional/laboratory use only. The Invivoscribe symposiums presented during the 25th European Hematology Association Virtual Congress are now available to watch on demand.

Utility of NGS Assays for the Evaluation of Lymphoid Malignancies – Webinar

Products are for professional/laboratory use only. This webinar will explore how insights gained through NGS translate to the development of improved treatment of lymphoid malignancies.

Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Products are for professional/laboratory use only. Press Release:  Mechelen, Belgium, 27 June 2018

Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Products are for professional/laboratory use only. A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).